Non-small Cell Lung Cancer study: RMC-9805 vs RMC-6236
Official title Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
ClinicalTrials.gov ID: NCT06040541
What this study is testing
What is RMC-9805?
RMC-9805 is an investigational oral tablet being studied for the treatment of KRAS G12D‑mutant non‑small cell lung cancer and other solid tumors.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study will look at how safe and well tolerated RMC‑9805 is, both by itself and together with RMC‑6236, in people with certain cancers that have a KRAS G12D mutation.
- Who it's for
- Adults who have KRAS G12D‑mutant solid tumors such as non‑small cell lung cancer, colorectal cancer, pancreatic ductal adenocarcinoma, or other advanced solid tumors.
- What's involved
- Participants will receive RMC‑9805, either alone or with RMC‑6236, and will have regular visits and tests to monitor safety and side effects.
- Time commitment
- The study will last for several months, with scheduled visits and tests throughout the treatment period.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Pathologically documented, locally advanced or metastatic solid tumor with a KRAS G12D-mutation
- Received and progressed or been intolerant to prior standard therapy (including targeted therapy) appropriate for tumor type and stage
- ECOG performance status 0 or 1
- Adequate organ function
You likely can't join if
- Primary central nervous system (CNS) tumors
- Known or suspected leptomeningeal or active brain metastases or spinal cord compression
- Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication
- Participant was previously treated with an investigational KRAS G12D inhibitor, pan- or multi-RAS inhibitor, or had prior therapy with any direct...
The study team makes the final eligibility decision.
Where it is enrolling
- Sacramento, California, United States
- New Haven, Connecticut, United States
- Sarasota, Florida, United States
- Tampa, Florida, United States
- Baltimore, Maryland, United States
- Boston, Massachusetts, United States
- New York, New York, United States
- Durham, North Carolina, United States
- Huntersville, North Carolina, United States
- Cincinnati, Ohio, United States
- Nashville, Tennessee, United States
- Dallas, Texas, United States
- Houston, Texas, United States
- San Antonio, Texas, United States
- Fairfax, Virginia, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Sacramento, California, United States; New Haven, Connecticut, United States; Sarasota, Florida, United States; Tampa, Florida, United States; Baltimore, Maryland, United States; Boston, Massachusetts, United States and 9 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.